MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Abbott Laboratories

Uždarymo kaina

SektoriusSveikatos priežiūra

131.61 -0.75

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

131.07

Max

132.62

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.6B

9.2B

Pardavimai

339M

11B

P/E

Sektoriaus vid.

17.363

63.778

Pelnas, tenkantis vienai akcijai

1.34

Dividendų pajamingumas

1.78

Pelno marža

84.099

Darbuotojai

114,000

EBITDA

82M

3B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+5.49% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.78%

2.39%

Kitas uždarbis

2025-04-16

Kitas dividendų mokėjimo data

2025-05-15

Kita Ex Dividend data

2025-04-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

7.8B

230B

Ankstesnė atidarymo kaina

132.36

Ankstesnė uždarymo kaina

131.61

Naujienos nuotaikos

By Acuity

27%

73%

75 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bullish Evidence

Abbott Laboratories Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-01-22 19:03; UTC

Uždarbis

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

2025-01-22 18:20; UTC

Uždarbis

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

2025-01-22 12:45; UTC

Uždarbis

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

2024-11-01 14:15; UTC

Pagrindinės rinkos jėgos

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

2024-11-01 10:10; UTC

Pagrindinės rinkos jėgos

Reckitt Shares Surge After Baby Formula Lawsuit Win

2024-10-31 23:57; UTC

Karštos akcijos

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

2024-10-31 23:14; UTC

Pagrindinės rinkos jėgos

Abbott Laboratories Shares Rise After Baby-Formula Verdict

2024-10-16 12:03; UTC

Uždarbis

Abbott Laboratories 3Q Sales Top Expectations

2025-02-01 18:14; UTC

Svarbiausios naujienos

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

2025-01-22 16:40; UTC

Svarbiausios naujienos
Uždarbis

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

2025-01-22 15:20; UTC

Uždarbis

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

2025-01-22 15:08; UTC

Uždarbis

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025-01-22 13:51; UTC

Uždarbis

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

2025-01-22 13:39; UTC

Svarbiausios naujienos
Uždarbis

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025-01-22 12:02; UTC

Uždarbis

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

2025-01-22 12:01; UTC

Uždarbis

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025-01-22 12:01; UTC

Uždarbis

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q Net $9.23B >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q Sales $10.97B >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q EPS $5.27 >ABT

2025-01-22 12:00; UTC

Uždarbis

Abbott Labs 4Q Adj EPS $1.34 >ABT

2025-01-22 09:54; UTC

Karštos akcijos

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

2024-11-01 17:33; UTC

Rinkos pokalbiai

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

2024-10-16 14:21; UTC

Svarbiausios naujienos
Uždarbis

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

2024-10-16 12:25; UTC

Uždarbis

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

2024-10-16 12:02; UTC

Svarbiausios naujienos
Uždarbis

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

2024-10-16 11:59; UTC

Uždarbis

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

2024-10-16 11:37; UTC

Uždarbis

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Akcijų palyginimas

Kainos pokytis

Abbott Laboratories Prognozė

Kainos tikslas

By TipRanks

5.49% į viršų

12 mėnesių prognozė

Vidutinis 139.93 USD  5.49%

Aukščiausias 158 USD

Žemiausias 117 USD

Remiantis 17 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Abbott Laboratories kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

17 ratings

15

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

127.64 / 133.46Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bullish Evidence

Vidutinės trukmės periodas

Strong Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

75 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.